دورية أكاديمية
أعرض في EDS

Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin.

التفاصيل البيبلوغرافية
العنوان: Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin.
المؤلفون: Shields MA; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Electronic address: mario.shields@northwestern.edu., Spaulding C; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA; Jesse Brown VA Medical Center, Chicago, IL, USA., Metropulos AE; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA., Khalafalla MG; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA., Pham TND; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA., Munshi HG; Department of Medicine, Feinberg School of Medicine, Northwestern University, 303 E. Superior Avenue, Lurie 3-220 or Lurie 3-117, Chicago, IL 60611, USA; The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA. Electronic address: h-munshi@northwestern.edu.
المصدر: Cell reports [Cell Rep] 2022 Mar 01; Vol. 38 (9), pp. 110441.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, c 2012-
مواضيع طبية MeSH: Carcinoma, Pancreatic Ductal*/drug therapy , Carcinoma, Pancreatic Ductal*/genetics , Carcinoma, Pancreatic Ductal*/metabolism , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/genetics , Pancreatic Neoplasms*/metabolism, Animals ; Cadherins/metabolism ; Carcinogenesis ; Cell Line, Tumor ; Disease Models, Animal ; GTP-Binding Protein alpha Subunits, G12-G13/metabolism ; Mice ; Proto-Oncogene Proteins p21(ras)/metabolism ; Sirolimus/pharmacology ; TOR Serine-Threonine Kinases/metabolism ; Pancreatic Neoplasms
مستخلص: Gα13 transduces signals from G-protein-coupled receptors. While Gα13 functions as a tumor suppressor in lymphomas, it is not known whether Gα13 is pro-tumorigenic or tumor suppressive in genetically engineered mouse (GEM) models of epithelial cancers. Here, we show that loss of Gα13 in the Kras/Tp53 (KPC) GEM model promotes well-differentiated tumors and reduces survival. Mechanistically, tumors developing in KPC mice with Gα13 loss exhibit increased E-cadherin expression and mTOR signaling. Importantly, human pancreatic ductal adenocarcinoma (PDAC) tumors with low Gα13 expression also exhibit increased E-cadherin expression and mTOR signaling. Treatment with the mTOR inhibitor rapamycin decreases the growth of syngeneic KPC tumors with Gα13 loss by promoting cell death. This work establishes a tumor-suppressive role of Gα13 in pancreatic tumorigenesis in the KPC GEM model and suggests targeting mTOR in human PDAC tumors with Gα13 loss.
Competing Interests: Declaration of interests The authors have declared that no conflict of interest exists.
(Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
References: J Exp Med. 2014 Mar 10;211(3):579-91. (PMID: 24590762)
Science. 2021 Sep 17;373(6561):1327-1335. (PMID: 34529489)
J Biol Chem. 2016 Jan 22;291(4):1605-1618. (PMID: 26589794)
Gastroenterology. 2013 Jun;144(6):1303-15. (PMID: 23622140)
Cancer Cell. 2005 May;7(5):469-83. (PMID: 15894267)
Nature. 2014 Dec 11;516(7530):254-8. (PMID: 25274307)
Life Sci. 2003 Dec 5;74(2-3):155-61. (PMID: 14607242)
J Mol Biol. 2016 Sep 25;428(19):3850-68. (PMID: 27515397)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Nat Cell Biol. 2018 Jul;20(7):811-822. (PMID: 29941929)
Cancer Med. 2018 Nov;7(11):5611-5620. (PMID: 30267476)
Methods Mol Biol. 2019;1882:161-169. (PMID: 30378053)
BMC Cancer. 2010 Jul 14;10:368. (PMID: 20630061)
Oncogene. 2016 Jul 21;35(29):3771-80. (PMID: 26616858)
J Biol Chem. 2020 Dec 4;295(49):16897-16904. (PMID: 33109615)
J Clin Pathol. 2012 May;65(5):431-6. (PMID: 22396552)
Oncogene. 2018 Mar;37(10):1340-1353. (PMID: 29255247)
Oncogene. 2016 May 5;35(18):2407-12. (PMID: 26257060)
Biochemistry. 2007 Jun 12;46(23):6677-87. (PMID: 17503779)
Nat Commun. 2017 Jan 19;8:13700. (PMID: 28102206)
Nat Rev Mol Cell Biol. 2008 Jan;9(1):60-71. (PMID: 18043707)
Gut. 2014 Sep;63(9):1481-9. (PMID: 24717934)
Oncogene. 1994 Sep;9(9):2559-65. (PMID: 8058319)
Ann Surg Oncol. 2013 Nov;20(12):3802-8. (PMID: 23846778)
Blood. 2016 Jun 2;127(22):2723-31. (PMID: 26989201)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Biochem Biophys Res Commun. 1994 Jun 15;201(2):603-9. (PMID: 8002992)
Ann Surg Oncol. 2003 Apr;10(3):284-90. (PMID: 12679314)
J Clin Oncol. 2009 Jan 10;27(2):193-8. (PMID: 19047305)
Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):141-50. (PMID: 21383670)
Cell. 2017 Apr 20;169(3):381-405. (PMID: 28431241)
Nat Med. 2003 Nov;9(11):1418-22. (PMID: 14528298)
Sci Transl Med. 2011 Jul 20;3(92):92ra66. (PMID: 21775669)
J Biochem. 2011 Oct;150(4):357-69. (PMID: 21873336)
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8173-8. (PMID: 16705036)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
Gastroenterology. 2018 Nov;155(5):1593-1607.e12. (PMID: 30142336)
Protein Sci. 2019 Feb;28(2):305-312. (PMID: 30345641)
Am J Physiol Renal Physiol. 2020 Mar 1;318(3):F660-F672. (PMID: 31984793)
Nat Rev Drug Discov. 2017 Dec;16(12):829-842. (PMID: 29075003)
Cancer Cell. 2003 Dec;4(6):437-50. (PMID: 14706336)
Cancers (Basel). 2021 Jan 25;13(3):. (PMID: 33503832)
Br J Pharmacol. 2020 Jun;177(11):2434-2455. (PMID: 32060895)
معلومات مُعتمدة: R21 CA255291 United States CA NCI NIH HHS; P30 CA060553 United States CA NCI NIH HHS; I01 BX002922 United States BX BLRD VA; T32 CA070085 United States CA NCI NIH HHS; R01 CA217907 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: E-cadherin; Gα13; KC mouse model; KPC mouse model; human PDAC tumors; mTOR; rapamycin
المشرفين على المادة: 0 (Cadherins)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
EC 3.6.5.1 (GTP-Binding Protein alpha Subunits, G12-G13)
EC 3.6.5.2 (Hras protein, mouse)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
W36ZG6FT64 (Sirolimus)
تواريخ الأحداث: Date Created: 20220302 Date Completed: 20220411 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8989626
DOI: 10.1016/j.celrep.2022.110441
PMID: 35235808
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-1247
DOI:10.1016/j.celrep.2022.110441